Anzeige
Mehr »
Login
Sonntag, 28.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Fokus auf Nurexone: High-Level Biotech im Pennystock-Kleid!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
28 Leser
Artikel bewerten:
(0)

China Animal Vaccine Industry Report 2016-2020 - Market is Expected to Hit Around RMB16.9 Billion in 2015 - Y-oY Increase of 20.7% - Research and Markets

DUBLIN, June 13, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "China Animal Vaccine Industry Report, 2016-2020" report to their offering.

The Chinese animal vaccine market size grew from RMB1.4 billion in 2004 to RMB14.0 billion in 2014 at a high rate of 25.9%, and is expected to hit around RMB16.9 billion in 2015, a year-on-year increase of 20.7%.

Despite a large number of animal vaccine companies (about 100) in China, the industry is less concentrated. In 2015, China Animal Husbandry Industry Co., Ltd. (CAHIC) held the largest share (7.4%) of the Chinese animal vaccine market in 2015, followed by Jinyu Bio-technology (7.2%), Qingdao Yebio Biological Engineering (5.0%), Xinjiang Tecon Animal Husbandry Bio-Technology (4.6%), Pulike Biological Engineering (2.8%), and Tianjin Ringpu Bio-technology (2.8%).

Although the Chinese animal vaccine market is primarily controlled by domestic companies with a share of 90% or so, the high-end vaccine market, such as pet vaccines, is occupied by foreign brands including Zoetis (formerly Pfizer's animal health division), Fort Dodge, Intervet, Merial, and BoehringerIngelheim. These foreign players not only directly sell vaccines in China but also have been increasing their investment in the country.

Moreover, great progress has been made in pet vaccines. Rabies vaccines, inactivated produced by Pulike Biological Engineering, Tianjin Ringpu Bio-technology, and Shanghai Hile Bio-Technology are expected to be approved and go on the market at the end of 2016 or in 2017.

China Animal Vaccine Industry Report, 2016-2020 highlights the followings:

- Global animal vaccine industry (market size/structure, competitive landscape, etc.)

- China's animal vaccine industry (market size/structure, competitive landscape, import/export, etc.)

- China's animal vaccine industry (policy environment, social environment, downstream demand, etc.)

- Market segments (pig vaccines, poultry vaccines) in China (market size, competitive landscape, etc.)

- 16 Chinese animal vaccine producers (operation, animal vaccine business, forecast & outlook, etc.)

- Chinese animal vaccine market and market segments (market size/structure forecast) during 2016-2020

Key Topics Covered:

1. Overview of Animal Vaccine

2. Status Quo of Animal Vaccine Industry

3. Development Environment for China Animal Vaccine Industry

4. Chinese Animal Vaccine Industry Segments

5 Key Enterprises

6. Summary and Forecast

Companies Mentioned

- CAHIC - Chopper

- Guangdong Winsun Bio-pharmaceutical

- Hile Bio - Jinyu Bio-technology

- Keqian Biology

- Nannong Hi-Tech

- Pulike

- Ringpu Bio-technology

- ShenghuaBiok

- Shenlian Biotechnology

- Tech-bank

- Tecon

- Weike Biotechnology

- Wens Dahuanong

- Yikang Biological

For more information visit http://www.researchandmarkets.com/research/fprdxv/china_animal

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.